TITLE

EASL Roundup

PUB. DATE
April 2012
SOURCE
BioWorld Today;4/20/2012, Vol. 23 Issue 77, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the results from a Phase III open-label trial of two anemia management strategies conducted by Merck and Co. Inc. for patients in treatment with Victrelis (boceprevir) and Pegintron (peginterferonalfa-2b) and ribavirin for hepatitis C virus.
ACCESSION #
75191173

 

Related Articles

  • Success of Vaccine Offers Promise of Cervical Cancer Prevention. Schultz, James // JNCI: Journal of the National Cancer Institute;1/15/2003, Vol. 95 Issue 2, p103 

    Cites the key findings of Merck and Company Inc.'s clinical trials on an investigational vaccine against the human papillomavirus type 16. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cervical cancer prevention.

  • Clinic Roundup.  // BioWorld Today;12/19/2011, Vol. 22 Issue 243, p7 

    This section offers news briefs on clinical trials including the preliminary data obtained by Advaxis Inc. from a Phase II trial of ADXS-HPV, the trial initiated by Merck & Co. Inc. and Roche AG to test drug combinations for chronic hepatitis C virus genotype 1 infection, and enrollment...

  • Merck reports encouraging results from Phase IIb insomnia study.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p17 

    The article reports on the results of the Phase IIb clinical trial conducted by Merck & Co. Inc. which showed that dual orexin receptor antagonist is effective for treatment of primary insomnia.

  • Merck Pulls the Plug on Depression Drug.  // Chemical Market Reporter;11/17/2003, Vol. 246 Issue 17, p2 

    Reports that Merck & Co. Inc. stopped the development of an investigational depression drug, MK-0869, after it failed to show efficacy in Phase III trials. Drugs sales of the company; Mode action of MK-0869; List of phase III products remaining in the Merck pipeline.

  • Merck, Pfizer combining drugs. Investor's Business Daily // Investors Business Daily;8/27/2014, pA02 

    The article reports on the plan of pharmaceutical company Merck & Co. Inc. to conduct clinical trials for brolizumab, an immunotherapy drug .

  • Packs more punch. Horton, Kathleen // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p100 

    Announces Merck & Co. Inc.'s presentation of the findings of the Phase III clinical trials on the anti-migraine drug Maxalt 10 mg (rizatriptan) at the 8th Congress of the International Headache Society.

  • MERCK & CO.  // MondayMorning;1/24/2011, Vol. 19 Issue 3, p11 

    The article reports on Merck & Co. Inc.'s decision of halting the study of anticlotting pill vorapaxar following the bleeding risks to patients with a history of strokes. It reports that the company stopped the study as the drug was linked to an increased risk of intracranial hemorrhage in...

  • Merck Launches Alzheimer's Trial.  // MondayMorning;12/10/2012, Vol. 20 Issue 47, p1 

    The article reports on the launch by Merck & Co. of a late-stage study on the treatment of Alzheimer's disease.

  • Bad seed? Critics say drug study more marketing than medicine.  // IRB Advisor;Nov2008, Vol. 8 Issue 11, p121 

    The article discusses the Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness (ADVANTAGE). It is suspected to be a seeding trial but Merck denied it by emphasizing the purpose of examining Vioxx. A seeding trial refers to a clinical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics